The synthesis of a new series of diaryl ureas having a pyrrolo [2,3-d]pyrimidine scaffold is reported here. The in vitro antiproliferative activities of these diaryl derivatives against human melanoma cell line A375 were tested and the effect of substituents on the phenyl ring was investigated. The para substituted compounds Ia-g showed superior or similiar activity to Sorafenib against the A375 cell line. Among these compounds, Ic-e showed excellent activity against A375 compared with Sorafenib, a multi-kinase inhibitor.
Introduction
Melanoma, the most aggressive form of skin cancer, is the fastest growing cancer in the United States.
1,2 Early stage melanoma can be cured surgically. However, melanoma metastasizing to major organs (stage IV) is virtually incurable. 2 Patients with disseminated melanoma have a median survival time of less than a year, and the estimated 5-year survival rate is less than 15%. 2, 3 With the incidence of melanoma rapidly rising in the United States and other developed countries, there is an urgent need to develop more effective drugs.
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Recently, Sorafenib, as well as other diaryl ureas, have been evaluated as potent and selective antiproliferative agents for the treatment of melanoma. [7] [8] [9] [10] [11] [12] The promising results have encouraged many research groups to investigate diaryl urea scaffolds to develop new derivatives for the treatment of cancer.
13-17 Accordingly, we have synthesized a new series of diaryl ureas, and report their antiproliferative activity against human melanoma cell line A375.
In this work, we investigate the effect that replacing the 2-(methylaminocarbonyl)-pyridine-4-yl-oxy group in Sorafenib with a pyrrolo [2,3-d] pyrimidine moiety has on the antiproliferative activity. The effect of substitution at the other phenyl urea ring is also investigated by using the different substituents R 1 and R 2 .
Results and Discussion

Chemistry. The general synthesis of pyrrolo [2,3-d] pyrimidine ureas and amides is shown in Scheme 1 and 2. The intermediate 2 was obtained by reduction of the thiol compound 1 18 using Raney nickel. Reaction of 2 with benzoyl chloride in pyridine produced the benzoyl protected compound 3a. The acetyl compound 3b was obtained by the coupling of 2 with acetic acid using EDC/HOBt. Preparation of the p-nitrophenyl compounds 4a and 4b was achieved by treating 3a and 3b with 1-iodo-4-nitrobenzene in the presence of potassium carbonate and copper iodide. Reduction of compound 4b with Pd-C/H 2 produced the amino compound 5b, whereas the reduction of compound 4a was carried out using tin(II)chloride to provide the desired compound 5a. The urea type compounds (Ia-c and Ih-i) were prepared by the reaction of compounds 5a and 5b with the corresponding isocyanates. The amides (Id-g and Ij) were obtained by condensation with the corresponding carboxylic acid using EDC/HOBt. The synthesis of the m-substituted urea and amide compounds (IIa-c and IId-i) was achieved in a way similar to that used for the preparation of p-compounds using the corresponding starting materials (Scheme 2).
In vitro activity. We examined the antiproliferative activities of these newly synthesized compounds human melanoma cell line A375. The ability of pyrrolo [2,3-d] pyrimidine derivatives to inhibit the growth of the A375 cell line is summarized in Tables 1 and 2 . We selected Sorafenib as the reference standard, because it has been used extensively in clinical trials for melanoma.
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The para substituted compounds Ia-g were superior or similiar to Sorafenib in activity against A375. Among these compounds, Ic-e showed excellent activity against A375 compared with Sorafenib. As to the substituent on the phenyl chain, the para substituted compounds Ia-g were generally more potent than the meta substituted compounds IIa-i. Comparing the linker, the compounds (Id and IId) having amide moieties were generally more potent than the urea compounds (Ia and IIa). The activity of the acetyl substituted compounds (Ih-j) against A375 was found to be inferior to that of amino compounds (Ia and Id).
Experimental Section
Melting points (mp) were determined on a Walden Precision Apparatus Electrothermal 9300 apparatus and were uncorrected.
1
H NMR spectral data were recorded using a Gemini 300 spectrometer. Mass spectra were recorded on a Waters 3100 Mass Detecter.
A375P cell culture and anti-proliferative activity of tested compound on A375P. A375P cells were purchased from American Type Culture Collection (ATCC, Rockville, MD, US) and maintained in a DMEM (Welgene, Daegu, Korea) supplemented with 10% FBS (Welgene) and 1% penicillin/streptomycin (Welene) in a humidified atmosphere with 5% CO 2 at 37 o C. A375P cells were taken from culture substrate with 0.05% trypsin-0.02% EDTA and plated at a density of 5 × 10 3 cells/well in 96 well plates and then incubated at 37 o C for 24 hours in a humidified atmosphere with 5% CO 2 prior to treatment of various concentration (three fold serial dilution, 12 points) of test compounds. The A375P cell viability was assessed by the conventional 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. MTT assays were carried out with CellTiter 96 ® (Promega) according to the manufacturer's instructions. The absorbance at 590 nm was recorded using EnVision2103 (PerkinElmer; Boston, MA, US). The IC 50 was calculated using GraphPad Prism 4.0 softwere.
.0 mmol) in water (50 mL) was added Raney nickel (3.0 g). The reaction mixture was heated at reflux for 4 h, and then the hot solution was filtered through celite. The Nikel residue was washed with further water (100 mL). The aqueous filtrate was evaporated to dryness to yield the product (0. suspension was warmed to room temperature and Et 3 N (1.6 mL, 11.4 mmol) were added. The mixture was stirred for 24 h at 80 o C. The suspension was poured into water and the aqueous layer was extracted with ethyl acetate (50 mL). The organic layer was washed with water (230 mL), then a solution of 5% NaOH (20 mL) and brine. The organic layer was separated, dried over Na 2 SO 4 . Evaporation of the solvent in vacuo gave a crude residue, which was purified by silica gel column chromatography (EtOAc) to give 3b (0.3 g, 45%) as a pale yellow oil. o C overnight and then cooled to room temperature. Most of the ethanol was removed in vacuo. The residue was diluted with ethyl acetate (30 mL), NaHCO 3 (100 mL) and water (50 mL), and then the organic layer was dried over anhydrous Na 2 SO 4 . The solvent was removed in vacuo, and purification was achieved by flash chromatography (EtOAc) to afford 5a (0. 7 mmol) in THF (10 mL) was added Pd/C (0.1 g) and was hydrogenated at 50 psi for 2 h, and then filtered through celite. The Pd/C residue was washed with further THF (10 mL) and concentration. The crude residue was purified by silica gel column chromatography (EtOAc) to give 5b (45 mg, 25%) as a pale yellow oil. The syntheses of compounds IIb-IIc were carried out by the same procedure as described for the preparation of IIa.
IIb: Yield 35%. mp: 225-226
